Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new drug stop transplant complications?

NCT ID NCT04572815

First seen Dec 12, 2025 · Last updated May 25, 2026 · Updated 29 times

Summary

This study tests whether the drug ustekinumab can prevent a serious side effect called graft-versus-host disease (GVHD) in adults receiving stem cell transplants for blood cancers. GVHD occurs when donor cells attack the patient's body. The trial involves 116 participants who receive either ustekinumab or a placebo after transplant. The goal is to see if the drug reduces severe GVHD and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center,

    Duarte, California, 91010, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida, 33612, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.